C1 Esterase Inhibitor (Berinert)

Berinert is covered for treatment of acute HAE attacks (FDA-approved) and for prophylaxis of HAE in patients with C1‑INH deficiency type I or II, and uses outside these indications are not supported. Coverage requires baseline labs showing functional C1‑INH <50% and low serum C4, prescription by or consultation with an HAE specialist/allergist‑immunologist, documentation of clinical benefit for reauthorization, 12‑month approval intervals, and dosing limited to up to 20 IU/kg IV no more than once daily.

"Berinert is indicated for the treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.